Fundamental Analysis of APTEVO THERAPEUTICS INC(NASDAQ:APVO) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to APVO. APVO was compared to 565 industry peers in the Biotechnology industry. While APVO seems to be doing ok healthwise, there are quite some concerns on its profitability. APVO has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year APVO has reported negative net income.

APVO had a negative operating cash flow in the past year.

APVO had negative earnings in 4 of the past 5 years.

In the past 5 years APVO always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of APVO (-153.26%) is worse than 86.45% of its industry peers.

Looking at the Return On Equity, with a value of -442.72%, APVO is doing worse than 78.79% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-153.26%
ROE	-442.72%
ROIC	N/A

ROA(3y)-32.3%

ROA(5y)-41.16%

ROE(3y)-812.67%

ROE(5y)-577.31%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for APVO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

APVO does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, APVO has more shares outstanding

Compared to 5 years ago, APVO has more shares outstanding

There is no outstanding debt for APVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

APVO has an Altman-Z score of -22.90. This is a bad value and indicates that APVO is not financially healthy and even has some risk of bankruptcy.

APVO has a worse Altman-Z score (-22.90) than 87.34% of its industry peers.

There is no outstanding debt for APVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-22.9

ROIC/WACCN/A

WACC8.5%

2.3 Liquidity

APVO has a Current Ratio of 1.92. This is a normal value and indicates that APVO is financially healthy and should not expect problems in meeting its short term obligations.

APVO has a Current ratio of 1.92. This is in the lower half of the industry: APVO underperforms 76.83% of its industry peers.

A Quick Ratio of 1.92 indicates that APVO should not have too much problems paying its short term obligations.

APVO has a worse Quick ratio (1.92) than 75.94% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.92
Quick Ratio	1.92

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

APVO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.88%, which is quite impressive.

Looking at the last year, APVO shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.

EPS 1Y (TTM)81.88%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%97.82%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 15.44% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y73%

EPS Next 2Y38.15%

EPS Next 3Y24.73%

EPS Next 5Y15.44%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APVO. In the last year negative earnings were reported.

Also next year APVO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

APVO's earnings are expected to grow with 24.73% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y38.15%

EPS Next 3Y24.73%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for APVO!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

APTEVO THERAPEUTICS INC

NASDAQ:APVO (11/22/2024, 8:23:36 PM)

After market: 0.2992 -0.01 (-2.76%)

0.3077

+0.04 (+15.33%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap5.70M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-153.26%
ROE	-442.72%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.92
Quick Ratio	1.92
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)81.88%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y73%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

APTEVO THERAPEUTICS INC (APVO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens